Aigen Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Aigen Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,675	Closed	-$616K	–	798
2025 Q3	$616K	Buy	+4,675	New	+$561K	0.1%	333
2024 Q3	–	Sell	-7,229	Closed	-$772K	–	865
2024 Q2	$772K	Buy	7,229 +5,069	+235%	+$557K	0.15%	187
2024 Q1	$260K	Buy	+2,160	New	+$265K	0.06%	478
2023 Q1	–	Sell	-1,389	Closed	-$221K	–	717
2022 Q4	$221K	Buy	+1,389	New	+$204K	0.03%	429
2021 Q4	–	Sell	-8,649	Closed	-$1.13M	–	1106
2021 Q3	$1.13M	Buy	+8,649	New	+$1.31M	0.22%	134
2020 Q1	–	Sell	-13,257	Closed	-$1.98M	–	1408
2019 Q4	$1.98M	Buy	+13,257	New	+$1.8M	0.33%	64

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Aigen Investment Management's JAZZ Position: Q4 2025 in Review

Aigen Investment Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2025, closing a stake of 4,675 shares — an estimated $616K sold.

Aigen Investment Management first reported a position in JAZZ in Q4 2019 and held it in 6 quarters. The position peaked at $1.98M in Q4 2019. 576 funds tracked by Wall St. Rank hold JAZZ as of Q4 2025.

Aigen Investment Management reported no remaining Jazz Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Aigen Investment Management sold 4,675 Jazz Pharmaceuticals shares in Q4 2025, an estimated $616K.
Aigen Investment Management first reported a position in Jazz Pharmaceuticals in Q4 2019 and held it in 6 quarters.
Aigen Investment Management's Jazz Pharmaceuticals position peaked at $1.98M in Q4 2019.
576 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2025.

Based on Aigen Investment Management's 13F filing for Q4 2025, filed 13 Feb 2026.